A b s t r a c t
The present study investigated the protein expression level of CXCL12 in colorectal cancer and aimed to elucidate its association with prognosis. CXCL12 positivity in 50% or more of tumor cells was defined as high expression and that in less than 50% of the tumor cells as low expression. CXCL12+ tumor budding at the invasive front was divided into 2 grades: high with 10 or more budding foci per ×200 field of view and low grade with fewer than 10 budding foci. Patients with high expression (72.7%) and high grade CXCL12+ tumor budding (43.0%) had significantly shorter survival than patients with low expression (P = .014) and low grade (P = .003), respectively. Patients with a combination of high expression and high grade had the worst outcome (P < .001). Our study demonstrated that CXCL12 expression in colorectal cancer cells and at sites of budding were significant prognostic factors. Furthermore, together with lymph node metastasis, a combination of both expression patterns was a more powerful independent prognostic factor.
Several studies have revealed that the establishment of metastasis is the final outcome of a series of phenomena including tumor cell deposition in distant organs, clonogenic growth, and angiogenesis. These processes are fundamental for tumor cell survival and tumor metastasis and are regulated by interactions of cancer cells with the host microenvironment. [1] [2] [3] The CXC chemokine ligand-12 (CXCL12), stromal cellderived factor-1, is a member of the CXC chemokine family, which has been initially cloned from murine bone marrow and characterized as a pre-B-cell growth-stimulating factor. [4] [5] [6] CXCL12 exerts effects through its physiologic cognate receptor, CXC chemokine receptor 4 (CXCR4), and is known to have roles in chemotaxis, 7 hematopoiesis, 8 and angiogenesis. 9, 10 In addition, CXCR4 is involved in tumor cell homing to specific organs and in tumor progression. [11] [12] [13] CXCL12/CXCR4 also has a critical role in determining the metastatic destination of breast cancer cells. 12 It is also evident that some CXCR4+ tumors, including colorectal cancer, 1,13,14 exhibit marked malignant behavior. 12, 15, 16 So far, few studies have focused on chemokine expression in cancer cells, [17] [18] [19] [20] [21] and little is known about the clinicopathologic significance of CXCL12 expression in patients with colorectal cancer.
In this study, we attempted to evaluate the clinicopathologic significance of CXCL12 expression in patients with colorectal cancer by using immunohistochemical analysis together with examination of conventional histopathologic features.
Materials and Methods
Between 1996 and 1997 at the National Cancer Center Hospital, Tokyo, Japan, 165 patients underwent surgery for primary colorectal carcinoma, including 100 colon (60.6%) Upon completion of this activity you will be able to:
• define the World Health Organization criteria for the histologic grading of the differentiation of colorectal carcinoma.
• discuss the role of examination of the invasive front of colorectal carcinoma for tumor budding and how this may pertain to prognosis.
• discuss the potential application of immunohistochemical staining for CXCL12 to highlight tumor budding in colorectal carcinoma.
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Questions appear on p 307. Exam is located at www.ascp.org/ajcpcme. All patients underwent curative resection, defined as the removal of gross cancer and the demonstration of tumornegative surgical margins by histopathologic examination of the total circumference. No patients received preoperative chemotherapy, and all patients were free of distant visceral metastases. The patients comprised 101 men and 64 women, ranging in age from 32 to 93 years (mean ± SD, 61.8 ± 11.2 years). Postsurgical follow-up studies were completed for all patients, with follow-up periods ranging from 3 to 2,544 days (median, 1,844 days). Postsurgical recurrence was diagnosed by ultrasonography and computed tomography. This study was approved by the National Cancer Center Ethics Committee, Tokyo, Japan.
All available routinely processed, formalin-fixed, and paraffin-embedded blocks of colorectal carcinoma were obtained. Sections containing the maximum diameter of the tumor were used in the present study. Age, sex, tumor location, tumor size, macroscopic type, depth of tumor invasion, tumor differentiation, tumor budding grade by H&E staining, lymphatic vessel invasion, blood vessel invasion, lymph node metastasis, liver metastasis, and lung metastasis were subjected to statistical analyses zTable 1z.
The grade of tumor differentiation was decided on the basis of the predominant component in the tumor according to the World Health Organization classification: the percentage of the tumor showing formation of gland-like structures can be used to define the grade; well differentiated (grade 1) lesions exhibit glandular structures in more than 95% of the tumor; moderately differentiated (grade 2) adenocarcinoma has 50% to 90% glands; poorly differentiated (grade 3) adenocarcinoma has 5% to 50%; and undifferentiated (grade 4) carcinoma has less than 5%. Mucinous adenocarcinoma and signet-ring cell carcinoma, by convention, are considered poorly differentiated (grade 3). 23 The existence of tumor budding at the invasive front was also evaluated. The invasive front in this study was defined as all regions of the border area between the primary tumor and interstitium in the submucosa, muscularis propria, subserosa, or nonperitonealized pericolonic/perirectal tissues. In accordance with previous studies, an isolated single cancer cell or a cluster composed of fewer than 5 cancer cells observed in the stroma of the actively invasive region was defined as a budding focus. [24] [25] [26] After reviewing the H&E-stained slides from each case, a field where the budding foci were most intense was selected. The number of budding foci was counted using a 20× microscope objective, giving a final magnification of ×200. A count ranging from 0 to 9 budding foci per field was designated as low grade and a count of 10 or more as high grade, in accordance with previous studies. 25, 26 
Immunohistochemical Studies
After deparaffinization, all sections were pretreated in citrate buffer (10 mmol/L, pH 6.0) at 121°C for 10 minutes for antigen retrieval. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in methanol for 20 minutes. The sections were then incubated with anti-CXCL12/SDF-1 monoclonal antibody (0.5 ng/mL; R&D Systems, Minneapolis, MN) at 4°C overnight. The immunostained sections were washed with phosphate-buffered saline and processed with an EnVision+ kit (DakoCytomation, Carpinteria, CA) in accordance with the manufacturer's instructions. Immunoproducts were visualized by using diaminobenzidine tetrahydrochloride, and the sections were counterstained with hematoxylin. As an internal positive control for CXCL12 staining, the immunopositivity of normal colorectal epithelia adjacent to the tumors and endothelial cells of blood vessels was used. Intensity of positive staining in tumor cells that was the same as or more than that in normal colorectal epithelia was considered positive. Sections from each paraffin block were used as negative control samples by replacing the primary antibody with normal mouse immunoglobulin. After immunohistochemical analysis, the tumors were categorized according to the ratio and localization of immunopositive tumor cells in the sections containing the maximum tumor diameter.
We examined the relationship between the CXCL12 positivity rate in tumor cells and various clinicopathologic factors and found that a cutoff value of 50% was the most powerful discriminatory factor. Accordingly, a cutoff index of 50% was selected for our study. When the proportion of tumor cells positive for CXCL12 was 50% or more, the tumor was defined as showing high CXCL12 expression, whereas tumors in which fewer than 50% of the cells were positive were defined as showing low CXCL12 expression.
In addition, CXCL12 expression in foci of tumor budding at the invasive front was quantified and scored by the same method as for evaluation of tumor budding grade using H&E-stained sections. After scanning each CXCL12-immunostained slide, a field where immunopositivity in the budding foci was the most intense was selected, and the number of CXCL12+ budding foci was counted at ×200 magnification. For all histopathologic variables, each macroscopic record and microscopic slide was analyzed by 2 experienced pathologists (Y.A.-F. and Y.N.) to reach a consensus.
Statistical Analysis
The relationships between clinicopathologic characteristics and the number of immunopositive tumor cells were analyzed by variance tests when appropriate. The χ 2 test was used to analyze variables such as sex, tumor location, depth of tumor invasion, tumor differentiation, tumor budding grade assessed by H&E staining, lymphatic vessel invasion, blood vessel invasion, lymph node metastasis, liver metastasis, and lung metastasis. The Student t test was used for statistical comparisons of variables such as age and tumor size, and the Mann-Whitney U test was applied to compare the variables of macroscopic type. Survival was measured from the date of surgery to the end of the follow-up period or death. Overall survival curves were determined by using the KaplanMeier method and were analyzed by using the log-rank test. Univariate and multivariate survival analysis was performed by using the Cox proportional hazards regression model with the StatView, version 5.0 software package (SAS Institute, Cary, NC), in a stepwise manner.
Results

Expression of CXCL12 in Colorectal Cancer
Immunoreactivity of CXCL12 was observed in the cell membrane and/or cytoplasm of tumor cells zImage 1Az. The endothelial cells of blood vessels and normal intestinal epithelia, especially in the middle to upper third portion of the crypt, * Data are given as number of cases or mean ± SD. P values were calculated by using the Mann-Whitney U test for age and maximum tumor diameter, the Student t test for macroscopic type, and the χ 2 test for all others. † According to the World Health Organization classification: 1, polypoid; 2, ulcerating circumscribed; 3, ulcerating infiltrative; 4, diffusely infiltrative. ‡ According to the International Union Against Cancer TNM classification: T2, tumor invades the muscularis propria; T3, tumor invades through the muscularis propria into the subserosa or into nonperitonealized pericolic or perirectal tissues; T4, tumor directly invades other organs or structures and/or perforates the visceral peritoneum. § According to the World Health Organization classification: grade 1, well-differentiated adenocarcinoma; grade 2, moderately differentiated adenocarcinoma; grade 3, poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma; grade 4, undifferentiated carcinoma.
were also positive for CXCL12. In addition, fibroblasts adjacent to cancer cells, as well as normal areas, were weakly positive, but their expression was significantly weaker than that of tumor cells. CXCL12 staining was localized diffusely or patchily, and CXCL12 was often expressed in tumor buds at the invasive front zImage 1Bz. The mean ± SD proportion of CXCL12+ tumor cells was 60.8% ± 27.3%. Of the 165 cases, 120 (72.7%) exhibited immunopositivity in 50% or more of the cancer cells.
Patients whose tumors had high CXCL12 expression had significantly shorter survival than patients whose tumors had low CXCL12 expression (P = .014 and P = .005, overall and recurrence-free survival rates, respectively; log-rank test) zFigure 1z. The correlations between the percentage of CXCL12 immunopositivity and clinicopathologic findings are shown in Table 1 . The percentage of CXCL12 immunopositivity was correlated with the depth of tumor invasion, tumor budding grade determined by H&E staining, and liver metastasis.
The results of univariate analysis using the Cox proportional hazards model are shown in zTable 2z. CXCL12 expression was found to be a significant prognostic factor for overall and recurrence-free survival, together with depth of tumor invasion, tumor budding grade by H&E staining, and lymph node metastasis. In addition, blood vessel invasion was found to be a significant predictive factor for recurrence, whereas lymphatic vessel invasion tended to be predictive of recurrence. Multivariate analysis using the Cox proportional hazards model revealed that the percentage of CXCL12 immunopositivity and lymph node metastasis were independent prognostic factors for overall and recurrence-free survival zTable 3z.
Grade of CXCL12 Immunopositivity in Foci of Tumor Budding
Of the 165 cases, 71 (43.0%) were defined as high grade, and the survival of the patients was significantly shorter than that of patients with low-grade tumors (P = .003 and P < .001, overall and recurrence-free survival rates, respectively; log-rank test) zFigure 2z. The number of CXCL12+ budding foci was correlated with the depth of tumor invasion (P < .001), tumor budding grade by H&E zImage 1z Immunohistochemical studies of CXCL12 in colorectal carcinoma. A, CXCL12 expression was observed in the cell membrane and cytoplasm of colorectal tumor cells. In this case, almost all tumor cells expressed CXCL12 (×45). B, CXCL12 expression was intense in tumor budding foci at the invasive front (×230).
zFigure 1z Kaplan-Meier survival curves of patients with colorectal carcinoma subdivided according to the proportion of tumor cells expressing CXCL12 (P = .014; log-rank test). staining (P < .001), lymph node metastasis (P = .003), and lung metastasis (P = .030) ( Table 1) . Univariate analysis using the Cox proportional hazards model revealed that the grade of CXCL12-immunopositive tumor budding was a significant prognostic factor (Table 2) . Multivariate analysis using the Cox proportional hazards model revealed that only lymph node metastasis was an independent prognostic factor for overall survival and that CXCL12+ tumor budding grade was not an independent factor for overall or recurrence-free survival zTable 4z.
Combination of CXCL12 Expression and CXCL12+ Tumor Budding Grade
Patients with high CXCL12 expression and high-grade tumors had significantly shorter survival than patients with other combinations (P < .001 and P < .001, overall and recurrence-free survival rates, respectively; log-rank test) zFigure 3z. This combination was correlated with the depth of tumor invasion (P < .001), tumor budding grade by H&E zFigure 2z Kaplan-Meier survival curves of patients with colorectal carcinoma subdivided according to the grade of CXCL12+ tumor budding (P = .003; log-rank test). staining (P < .001), lymph node metastasis (P = .022), and lung metastasis (P = .014). In addition, it showed a tendency to be correlated with liver metastasis (P = .052) ( Table  1) . Univariate analysis using the Cox proportional hazards model revealed that the combination of CXCL12 expression and CXCL12+ tumor budding grade was a significant prognostic factor (Table 2 ). Multivariate analysis using the Cox proportional hazards model revealed that the combination of CXCL12 expression and CXCL12+ tumor budding grade was an independent and significant prognostic factor for overall survival, together with lymph node metastasis, and also an independent prognostic factor for recurrence zTable 5z.
Discussion
CXCL12 expression in colorectal cancer cells and at foci of tumor budding was found to be an independent predictive factor for cancer recurrence and poor survival. The present study indicated that CXCL12 expression in tumor cells was correlated with liver metastasis and was an independent prognostic factor together with lymph node metastasis. As it has been demonstrated that CXCL12 promotes tumor growth and malignancy, 21 colorectal cancers exhibiting high CXCL12 expression seem to show aggressive biologic behavior, with poor patient survival. To our knowledge, correlations between CXCL12 expression and long-term survival have been recognized in breast carcinoma, 21 lymph node metastasis, and lung metastasis and tended to be correlated with liver metastasis. Moreover, this combination was an independent and significant prognostic factor for overall survival, together with lymph node metastasis, and also an independent prognostic factor for recurrence. In our study, only a few grade 3 and 4 cases (5 of 165 cases) were included. Therefore, it seems possible that tumor differentiation did not affect the results of analyses. In general, the majority of colorectal carcinomas are diagnosed as grade 1 or 2, and the majority of grade 3 or 4 cases are included among cases that are more advanced than stage II or III.
In the present study, CXCL12 was expressed distinctly in colorectal cancer cells, normal epithelium of the colon (especially in the middle to upper third of each crypt in the mucosal layer), and blood and lymphatic endothelial cells and weakly in fibroblasts. Previous reports indicated that CXCL12 was constitutively expressed in various organs, including lymph nodes, lung, liver, thymus, and stromal cells such as fibroblasts, endothelial cells, and osteoblasts in bone marrow. 4, 6, 12 Multiple biologic activities of CXCL12 have also been described. [7] [8] [9] [10] For example, in vitro studies have shown that CXCL12 can modulate tumor cell proliferation and migration. 11, 33, 34 CXCL12 probably stimulates the formation of capillary-like structures by human vascular endothelial cells. 9, 35, 36 In addition, hypoxia-dependent up-regulation of the chemokine receptor CXCR4 practically promotes breast cancer invasion and organ-specific metastasis. 37, 38 Colorectal carcinoma cells, especially those at the invasive front, are likely to be situated in a hypoxic milieu. 39, 40 Therefore, this may lead to further tumor invasion through up-regulation of CXCL12/CXCR4. CXCL12 expression in colorectal cancer cells and the grading of CXCL12 immunopositivity at foci of tumor budding are each significant prognostic factors. However, our present results suggest that, in colorectal carcinoma, CXCL12 expression used in combination with tumor budding grade is a more powerful prognostic indicator than either factor alone. carcinoma, 19 glioma, 20 esophageal carcinoma, 17 and gastric carcinoma. 18 Immunohistochemical staining of frozen breast cancer tissues has demonstrated CXCL12 mostly in tumor cells and stromal cells, and the level of CXCL12 transcription in the tumor is correlated significantly with overall survival and incidence-free survival. 21 In addition, in this study, we noted that CXCL12 expression was stronger at the invasive front than in other areas of colorectal cancer, reflecting the fact that the invasive front shows the most active interaction between cancer and stroma. We therefore further focused on CXCL12 expression at sites of tumor budding.
Tumor budding has been reported to be related to metastatic activity 27, 28 and prognostic outcome. 26, 29 Although previous studies have addressed the prognostic impact of tumor budding, the assessment of tumor budding was done by counting tumor budding foci 24, 25, 30 or scoring the degree of tumor budding. 29, 31, 32 However, for objective quantification of tumor budding, it is necessary to apply immunostaining with the keratin cocktail AE1/AE3 and/ or low-molecular-weight keratins (CAM5.2 [cytokeratins 8 and 18] ). This approach highlights tumor buds extremely well and allows easy selection of counting areas and easy and rapid counting. 24, 31 However, immunostaining with AE1/AE3 and/or CAM5.2 does not reflect the biologic activity of the tumor because all of the tumor cells are immunopositive.
In this study, we were able to count the numbers of tumor budding foci more easily than by H&E staining by using immunohistochemical analysis for CXCL12. CXCL12 immunostaining was used not only to highlight tumor cells but also to examine their potential aggressiveness by counting the number that were CXCL12+. CXCL12+ tumor budding grade was also correlated with the depth of tumor invasion, tumor budding grade determined by H&E staining, lymph node metastasis, and lung metastasis. CXCL12+ tumor budding grade was also demonstrated to be a prognostic indicator for overall survival and recurrence, although multivariate analysis showed that it was not an independent factor. One reason why CXCL12+ tumor budding grade was not an independent factor may have been that the grade was judged in only 1 area where the budding foci were most intense and, therefore, probably did not reflect the properties of the whole tumor. Therefore, we combined the grading of CXCL12 immunopositivity for tumor buds with the proportion of tumor cells expressing CXCL12. We found that patients whose tumors showed high CXCL12 expression and high grade had the worst outcome. The combination of CXCL12 expression and CXCL12+ tumor budding grade was further correlated with the depth of tumor invasion, tumor budding grade determined by H&E staining,
